Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Roche stories

Oct 25, 2026

Roche's divarasib cuts death risk 44% in lung cancer trial vs Amgen, Bristol Myers drugs

Roche's next-generation KRAS G12C inhibitor divarasib reduced the risk of death by 44% compared to current treatments in previously treated mutant non-small cell lung cancer patients, with median overall survival reaching nearly 6 months longer than competitors.

Oct 25, 2026·4 sources
00
Oct 23, 2026

Novartis multiple sclerosis drug remibrutinib shows weaker-than-expected relapse reduction

Novartis' oral multiple sclerosis drug remibrutinib meaningfully reduced relapses in patients but showed less efficacy than expected in phase 3 trials, potentially giving competitor Roche an advantage with its rival treatment.

Oct 23, 2026·4 sources
00

Roche licenses Zymeworks' experimental lung cancer drug ZW209 in deal worth up to $813 million

Roche has entered into a global license and collaboration agreement with Zymeworks for ZW209, a trispecific T cell engager targeting DLL3 for lung cancer treatment. The deal includes $55 million upfront, up to $718 million in milestone payments, and tiered royalties on future sales.

Oct 23, 2026·5 sources
00
Oct 19, 2026

Roche partners with Hansoh Pharma in deal worth over $15 billion

Roche has entered a partnership and licensing deal with China's Hansoh Pharmaceutical worth potentially more than $15 billion, covering a portfolio of antibody-drug conjugates across multiple cancer types.

Oct 19, 2026·3 sources
00
Oct 13, 2026

Roche licenses obesity drug from China's Rona Therapeutics for up to $1.2 billion

Roche entered a licensing agreement worth up to $1.16 billion with Chinese biotech Rona Therapeutics for an investigational RNAi-based obesity drug candidate, marking Roche's seventh China deal this year.

Oct 13, 2026·3 sources
00
Oct 8, 2026

Roche partners with Defand Therapeutics in $1 billion degrader deal, fourth China partnership since August

Roche has signed a deal worth up to $1 billion with Hangzhou-based Defand Therapeutics to develop molecular glue degraders for oncology and immunology, with less than $10 million upfront. This marks Roche's fourth partnership with a Chinese biotech company in seven weeks.

Oct 8, 2026·2 sources
00
Oct 7, 2026

Zealand Pharma and Roche's amylin drug achieves 9.2% weight loss in Phase 2 trial

Zealand Pharma and Roche reported that their experimental amylin drug helped patients with type 2 diabetes lose up to 9.2% of body weight in a mid-stage trial, as they seek to compete with Eli Lilly in the obesity and diabetes market.

Oct 7, 2026·2 sources
00
Oct 5, 2026

Roche licenses Alector's Parkinson's disease therapy for up to $1.27 billion

Swiss drugmaker Roche will pay up to $1.27 billion to license Alector's experimental treatment for Parkinson's disease, with $100 million upfront. The deal sent Alector's shares surging over 70% in premarket trading.

Oct 5, 2026·4 sources
00
Sep 28, 2026

FDA approves obinutuzumab for idiopathic nephrotic syndrome, first new treatment in 70 years

The FDA has approved Roche's obinutuzumab (Gazyva), an anti-CD20 agent, for treating idiopathic nephrotic syndrome in patients as young as 2 years old. This marks the first new drug approval for this kidney condition in seven decades.

Sep 28, 2026·2 sources
00
Sep 25, 2026

Genentech inks $1.5 billion bispecific antibody deal with Earendil Labs

Roche's Genentech is paying Earendil Labs $55 million upfront in a research collaboration to discover and develop multiple bispecific antibody cancer therapies. The oncology-focused deal includes milestone payments that could bring its total value to over $1.5 billion.

Sep 25, 2026·4 sources
00
Sep 24, 2026

Roche signs drug discovery deal with Atavistik Bio worth up to $2 billion

Swiss drugmaker Roche has entered a partnership with Atavistik Bio potentially worth nearly $2 billion, including milestone payments, to develop oral treatments for cardiovascular, kidney and metabolic diseases. The deal includes $70 million upfront with an additional $1.9 billion in potential milestone payments.

Sep 24, 2026·6 sources
00
Sep 23, 2026

Roche kidney disease drug succeeds in Phase 3 trial for IgA nephropathy

Roche's experimental RNA drug sefaxersen significantly reduced proteinuria in a late-stage trial for IgA nephropathy, positioning the company to bring a new treatment to market for the autoimmune kidney disease that currently has limited approved therapies.

Sep 23, 2026·3 sources
00
Sep 22, 2026

Roche's obesity drug enicepatide cuts body weight 15.5% in mid-stage trial

Roche's experimental obesity shot enicepatide reduced blood sugar and body weight by 15.5% in type-2 diabetes patients in a mid-stage trial, with a meaningful proportion reaching normalized glucose levels within less than a year of treatment.

Sep 22, 2026·2 sources
00
Sep 17, 2026

Roche's Lunsumio meets primary endpoint in phase 3 follicular lymphoma trial

Roche announced that its T-cell engager Lunsumio successfully met the primary endpoint in a confirmatory phase 3 trial for earlier-line follicular lymphoma treatment. The company is now pursuing a label expansion for the drug based on these positive results.

Sep 17, 2026·2 sources
00

Roche, Dualitas partner on $1B bispecific antibody discovery deal

Roche will collaborate with Dualitas to screen over 300,000 bispecific antibody combinations for inflammatory and immunology conditions in a deal worth up to $1 billion.

Sep 17, 2026·2 sources
00
Sep 1, 2026

Roche licenses tri-specific antibody from Simcere for blood cancer

Roche signed a global licensing agreement with China's Simcere for an experimental tri-specific antibody targeting blood cancers, expanding its oncology pipeline.

Sep 1, 2026·2 sources
00
Aug 24, 2026

Roche gains rights to Hanmi obesity drug that preserves muscle mass

Roche acquired rights to Hanmi Pharmaceutical's obesity drug for $190 million upfront and up to $2.3 billion total. The drug is designed to activate receptors in skeletal muscle to increase muscle mass while reducing fat, addressing a key concern with current GLP-1 weight loss medications.

Aug 24, 2026·2 sources
00

FDA clears Roche and Eli Lilly's blood test for Alzheimer's disease detection

The FDA has cleared a blood test developed by Roche and Eli Lilly to help identify signs of Alzheimer's disease in people aged 55 and older with cognitive decline.

Aug 24, 2026·3 sources
00
Jul 2, 2026

Roche's divarasib outperforms Amgen and Bristol Myers Squibb drugs in Phase 3 lung cancer trial

Roche announced positive results from a head-to-head Phase 3 trial showing its KRAS G12C inhibitor divarasib demonstrated superior efficacy compared to competing treatments from Amgen and Bristol Myers Squibb in patients with KRAS-driven lung cancer.

Jul 2, 2026·4 sources
00
Jun 29, 2026

Roche Launches Axelios Gene Sequencer to Challenge Illumina's Market Dominance

Swiss pharmaceutical giant Roche launched its long-awaited Axelios gene sequencer, aiming to break Illumina's leadership position in the next-generation sequencing market.

Jun 29, 2026·1 source
00
Jun 8, 2026

Roche enters licensing deal with Nurix Therapeutics for blood cancer drug worth up to $2.3-3 billion

Swiss pharmaceutical giant Roche has signed an exclusive licensing and collaboration agreement with Nurix Therapeutics for bexobrutinib, a protein degrader drug targeting B cell malignancies and blood cancers. The deal value is reported as up to $2.3 billion by one source and up to $3 billion by another.

Jun 8, 2026·2 sources
00
May 9, 2026

Roche to Acquire AI Pathology Company PathAI for $750 Million

Roche has signed a deal to acquire PathAI, an artificial intelligence company focused on helping pathologists diagnose diseases, for $750 million to accelerate its use of AI in diagnostics.

May 9, 2026·1 source
00
Apr 22, 2026

Roche Presents Multiple Sclerosis Drug Data Ahead of Regulatory Submission

Swiss drugmaker Roche presented latest clinical trial data for its experimental multiple sclerosis drug at a major conference, setting the stage for regulatory approval submissions, though safety questions remain under scrutiny.

Apr 22, 2026·1 source
00
Apr 17, 2026

Roche Launches New Phase 3 Trial of Elevidys for European Approval

Roche is initiating another Phase 3 clinical trial of the controversial Duchenne muscular dystrophy gene therapy Elevidys, aiming for potential approval in European markets.

Apr 17, 2026·1 source
00
Apr 16, 2026

FDA Petition Seeks to Revoke Approval of Roche's Ocrevus for Primary Progressive Multiple Sclerosis

The FDA is reviewing a petition to revoke approval of ocrelizumab (Ocrevus), Roche's top-selling drug, for treating primary progressive MS, raising questions about whether the drug may be causing more harm than good in this patient population.

Apr 16, 2026·1 source
00

Top claims

  • ▪In the Phase III Krascendo 1 trial involving 338 patients with previously treated KRAS G12C-mutated non-small cell lung cancer, Roche's divarasib reduced the risk of death by 44% compared to approved KRAS G12C inhibitors sotorasib and adagrasib
  • ▪The Phase III Krascendo 1 trial directly tested Roche's divarasib against Amgen Inc.'s sotorasib and Bristol-Myers Squibb Co.'s adagrasib, rather than comparing it against chemotherapy
  • ▪Roche announced it is working with health authorities to bring divarasib to patients following the Phase III Krascendo 1 trial results

Topics

Targeted cancer therapyCancer & OncologyClinical trialsCancer treatment breakthroughsPharmaceutical IndustryMarket competitionDrug Policy, Pricing & ApprovalClinical trial designDrug developmentAutoimmune diseaseNeurological disordersBiotech innovationMergers & acquisitions (M&A)Cancer treatmentCancer immunotherapyOncologyChina tech & industrial strategyChina-United States relationsWeight managementEli LillyMetabolic healthFDA drug approvalDrug Approval and Clinical TrialsPharmaDrug discoveryClinical Trial Design & EvaluationClinical evaluationGLP-1 / Weight-Loss MedicationsWeight loss medications & GLP-1 drugsLifestyle, Wellness and NutritionGLP-1 medicationsBlood sugar & insulinImmunotherapyClinical trial endpointsHematology & Blood CancersAlzheimer’s & dementiaPreventive medicineLongevity & biohackingCancer TypesFDA regulation & drug policyRegulatory complianceGovernment and Regulatory PolicyPublic healthcareAI startupsAIAI in healthcareFDA drug approval processNew drug application (NDA) processDrug safetyUS healthcare regulationGene therapy

Related entities

AdagrasibMadridSotorasibMultiple sclerosisChinaHangzhouChinaSwitzerlandAutoimmune diseaseEuropeUnited States